Vitamin D and Parkinson's disease—A hypothesis

Parkinson's disease (PD), a common disease of the elderly, is a movement disorder characterized by tremor, akinesia, and loss of postural reflexes, leading to immobility and frequent falls. It results from selective loss (death) of dopaminergic neurons in the substantia nigra region of the brain, largely developed prior to clinical diagnosis, and continuous after diagnosis, despite use of current therapeutic modalities. In PD in the United States the cause and mechanism of continued neuron cell death in the substantia nigra is currently unknown. We hypothesize, based upon several lines of evidence, that documented chronically inadequate vitamin D intake in the United States, particularly in the northern states and particularly in the elderly, is a significant factor in the pathogenesis of PD. This hypothesis implies that dietary aid for prevention and therapy for PD is possible. © 2006 Movement Disorder Society

[1]  W. Koller,et al.  Falls and Parkinson's disease. , 1989, Clinical neuropharmacology.

[2]  G. Román,et al.  Worldwide occurrence of Parkinson's disease: an updated review. , 1993, Neuroepidemiology.

[3]  B. Hoffer,et al.  Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats , 2001, Brain Research.

[4]  R. Vieth,et al.  Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it , 2001, European Journal of Clinical Nutrition.

[5]  J. McNeal,et al.  Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. , 2001, Cancer research.

[6]  S. Ozgoçmen,et al.  Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity , 2005, Journal of Bone and Mineral Metabolism.

[7]  P. Elias,et al.  25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. , 2004, The Journal of investigative dermatology.

[8]  S. Brimijoin,et al.  1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo , 1998, Brain Research.

[9]  S. P. Chow,et al.  Sequential fractures of both hips in elderly patients--a prospective study. , 1992, The Journal of trauma.

[10]  T. Veenstra,et al.  Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord , 1999, Journal of Chemical Neuroanatomy.

[11]  F. Sim,et al.  Prosthetic replacement of the femoral head for fracture of the femoral neck in patients who have Parkinson disease. , 1988, The Journal of bone and joint surgery. American volume.

[12]  C. Barton,et al.  Vitamin D fortification in the United States and Canada: current status and data needs. , 2004, The American journal of clinical nutrition.

[13]  Carly M. Kemmis,et al.  Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. , 2006, The Journal of nutrition.

[14]  J. McGrath,et al.  Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.

[15]  P. Trouillas,et al.  Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy , 1997, Movement disorders : official journal of the Movement Disorder Society.

[16]  L. Chia,et al.  Bone mineral density in patients with Parkinson's disease measured by dual photon absorptiometry , 1994, Nuclear medicine communications.

[17]  D. Zehnder,et al.  Vitamin D and barrier function: a novel role for extra-renal 1α-hydroxylase , 2004, Molecular and Cellular Endocrinology.

[18]  A. Howie,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Extrarenal Expression of 25-Hydroxyvitamin , 2022 .

[19]  François Berger,et al.  New clues about vitamin D functions in the nervous system , 2002, Trends in Endocrinology & Metabolism.

[20]  P. Goldberg Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence: (A viewpoint) part 2. biochemical and genetic factors , 1974 .

[21]  W. Rocca,et al.  Prevalence of Parkinson's disease in junín, Buenos Aires province, argentina , 1997, Movement disorders : official journal of the Movement Disorder Society.

[22]  C. Buncher,et al.  Birthplace as a risk factor in motor neurone disease and Parkinson's disease. , 1993, International journal of epidemiology.

[23]  A. Sadovnick,et al.  Vitamin D intake and incidence of multiple sclerosis , 2004, Neurology.

[24]  T. Hayashi,et al.  Vitamin D3 attenuates cortical infarction induced by middle cerebral arterial ligation in rats , 2000, Neuropharmacology.

[25]  A. Norman Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. , 1998, The American journal of clinical nutrition.

[26]  J. Kurtzke,et al.  Parkinsonism death rates by race, sex, and geography , 1988, Neurology.

[27]  J. De Pedro-Cuesta,et al.  Prevalence of Parkinson's disease in lower Aragon, Spain , 1999, Movement disorders : official journal of the Movement Disorder Society.

[28]  C. Weaver,et al.  Vitamin D requirements: current and future. , 2004, The American journal of clinical nutrition.

[29]  M. Holick,et al.  Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. , 2004, The American journal of clinical nutrition.

[30]  H. Bidmon,et al.  Vitamin d nuclear binding to neurons of the septal, substriatal and amygdaloid area in the siberian hamster (Phodopus sungorus) brain , 1992, Neuroscience.

[31]  Kwang-Soo Lee,et al.  Association of Vitamin D Receptor Gene Polymorphism and Parkinson's Disease in Koreans , 2005, Journal of Korean medical science.

[32]  P. Goldberg Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. (A viewpoint). Part 1. Sunlight, dietary factors and epidemiology. , 1974 .

[33]  M. F. Stewart,et al.  Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line. , 1994, The Journal of clinical endocrinology and metabolism.

[34]  J. Aita,et al.  Why patients with Parkinson's disease fall. , 1982, JAMA.

[35]  Mary Frances Picciano,et al.  Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. , 2004, American journal of epidemiology.

[36]  W. Stumpf,et al.  1,25(OH)2 vitamin D3 sites of action in the brain , 1987, Histochemistry.

[37]  M. Calvo,et al.  Dietary recommendations to meet both endocrine and autocrine needs of Vitamin D , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[38]  R. Koerfer,et al.  Putting cardiovascular disease and vitamin D insufficiency into perspective , 2005, British Journal of Nutrition.

[39]  Intakes for Calcium , Phosphorus , Magnesium , Vitamin D , and Fluoride , 1974 .

[40]  A. Chaudhuri Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis. , 2005, Medical hypotheses.

[41]  J. McGrath,et al.  Vitamin D: the neglected neurosteroid? , 2001, Trends in Neurosciences.

[42]  L. Airas,et al.  25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis , 2005, Multiple sclerosis.

[43]  J. Kurtzke,et al.  Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis , 1987, Neurology.

[44]  J. Y. Wang,et al.  Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. , 2001, Brain research.

[45]  M. Cantorna,et al.  Mounting Evidence for Vitamin D as an Environmental Factor Affecting Autoimmune Disease Prevalence , 2004, Experimental biology and medicine.

[46]  B. Djahanguiri,et al.  The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.

[47]  E. Bajna,et al.  25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis , 2001, Steroids.

[48]  M. Holick Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. , 2004, The American journal of clinical nutrition.

[49]  A. Zittermann Vitamin D in preventive medicine: are we ignoring the evidence? , 2003, The British journal of nutrition.

[50]  B. Hollis Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. , 2005, The Journal of nutrition.

[51]  W. Pardridge,et al.  Restricted Transport of Vitamin D and A Derivatives Through the Rat Blood‐Brain Barrier , 1985, Journal of neurochemistry.

[52]  T. Veenstra,et al.  1,25-dihydroxyvitamin D3 regulates the expression of N-myc, c-myc, protein kinase C, and transforming growth factor-beta2 in neuroblastoma cells. , 1997, Biochemical and biophysical research communications.

[53]  D. Raiten,et al.  Vitamin D and health in the 21st century: bone and beyond. Executive summary. , 2004, The American journal of clinical nutrition.

[54]  Yoshihiro Sato,et al.  Risk factors for hip fracture among elderly patients with Parkinson’s disease , 2001, Journal of the Neurological Sciences.

[55]  A. Embry Vitamin D Supplementation in the Fight Against Multiple Sclerosis , 2022 .

[56]  J L Kelsey,et al.  Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. , 1991, The New England journal of medicine.

[57]  A. Mackay-Sim,et al.  Vitamin d3 and brain development , 2003, Neuroscience.

[58]  P. Brachet,et al.  1,25‐Dihydroxyvitamin D3, an inducer of glial cell line‐derived neurotrophic factor , 1996, Neuroreport.

[59]  S. Kikuchi,et al.  Effect of 1,25‐dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L‐buthionine sulfoximine and 1‐methyl‐4‐phenylpyridine , 2000, Journal of neuroscience research.

[60]  A. Howie,et al.  Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1 , 2001 .

[61]  S. Brimijoin,et al.  Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells. , 1997, Brain research. Developmental brain research.

[62]  R. Tardiman,et al.  Hip fractures in patients with Parkinson's syndrome. , 1983, The Journal of trauma.

[63]  K. Radhakrishnan,et al.  Epidemiology of Parkinson's disease in Benghazi, North-East Libya , 1986, Clinical Neurology and Neurosurgery.

[64]  S. Emans,et al.  Prevalence of vitamin D deficiency among healthy adolescents. , 2004, Archives of pediatrics & adolescent medicine.

[65]  K. Dodd,et al.  Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health Interview Survey results. , 2004, Journal of the American Dietetic Association.

[66]  P. Lips Which circulating level of 25-hydroxyvitamin D is appropriate? , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[67]  R. Lea,et al.  VARIATION IN THE VITAMIN D RECEPTOR GENE IS ASSOCIATED WITH MULTIPLE SCLEROSIS IN AN AUSTRALIAN POPULATION , 2005, Journal of neurogenetics.

[68]  A. Kalueff,et al.  Increased anxiety in mice lacking vitamin D receptor gene , 2004, Neuroreport.

[69]  W. Stumpf,et al.  OH ) 2 vitamin D 3 sites of action in the brain An autoradiographic study , 2022 .

[70]  P. Huet,et al.  Apparent [3H]1,25-dihydroxyvitamin D3 uptake by canine and rodent brain. , 1983, The American journal of physiology.

[71]  H. Cross,et al.  Vitamin D and calcium deficits predispose for multiple chronic diseases , 2005, European journal of clinical investigation.

[72]  W. Willett,et al.  Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. , 2006, The American journal of clinical nutrition.

[73]  G. Rice,et al.  A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[74]  L. Svenson,et al.  Geographic Variations in the Prevalence Rates of Parkinson’s Disease in Alberta , 1993, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[75]  H. Pols,et al.  Vitamin D , 1928, Calcified Tissue International.

[76]  R. Perez-Fernandez,et al.  1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. , 2002, Brain research. Molecular brain research.

[77]  H. Kim Finite-amplitude surface waves on a thin film flow subject to a unipolar-charge injection , 2005 .

[78]  R. Houlgatte,et al.  1,25‐Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis , 1991, Journal of neuroscience research.

[79]  E. Gunter,et al.  Hypovitaminosis D in medical inpatients. , 1998, The New England journal of medicine.

[80]  K. Prufer,et al.  Vitamin D receptor and retinoid X receptor interactions in motion. , 2002, Vitamins and hormones.

[81]  M. Campbell,et al.  Biological actions of extra-renal 25-hydroxyvitamin D-1α-hydroxylase and implications for chemoprevention and treatment , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[82]  M. Haussler,et al.  Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. , 1988, Endocrinology.

[83]  D. Eyles,et al.  Vitamin D receptor expression in the embryonic rat brain , 2003 .

[84]  Anthony W. Norman,et al.  Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model , 2004, Nature Reviews Drug Discovery.

[85]  A. Mackay-Sim,et al.  Behavioural characterization of Vitamin D receptor knockout mice , 2005, Behavioural Brain Research.

[86]  J. Templeton,et al.  Hip fractures in patients with Parkinson's disease. , 1980, Clinical orthopaedics and related research.

[87]  M. Holick,et al.  25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue , 2001, The Lancet.

[88]  R. Heaney,et al.  Long-latency deficiency disease: insights from calcium and vitamin D. , 2003, The American journal of clinical nutrition.

[89]  C. Kao,et al.  A comparative study of 99Tcm‐HMPAO and 99Tcm‐ECD as a leukocyte labelling agent , 1994, Nuclear medicine communications.

[90]  C. Polman,et al.  Multiple sclerosis and vitamin D: an update , 2004, European Journal of Clinical Nutrition.

[91]  Yoshihiro Sato,et al.  High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease , 1997 .

[92]  F. Ishizaki,et al.  Relationship between osteopenia and clinical characteristics of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[93]  Edward Giovannucci,et al.  Vitamin D and prevention of colorectal cancer , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[94]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[95]  O Johnell,et al.  Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. , 1992, Age and ageing.